IntoCell
Latest round
- Series C
Last raised
- Dec 2020
Total raised
- $48M
Investors
- 14
About IntoCell
Founded in 2015 and based in Daejeon, South Korea, IntoCell operates as a researcher and developer of anti-cancer drugs that utilize linker technology that eliminates cancer cells in the human body.
Who invested in IntoCell
14 investors across 5 rounds
See all investors in IntoCell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about IntoCell
Who invested in IntoCell?
IntoCell has 14 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IntoCell raised?
IntoCell has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did IntoCell last raise money?
IntoCell's most recent round on record is a Series C, in Dec 2020.
What does IntoCell do?
Founded in 2015 and based in Daejeon, South Korea, IntoCell operates as a researcher and developer of anti-cancer drugs that utilize linker technology that eliminates cancer cells in the human body.
Where is IntoCell headquartered?
IntoCell is headquartered in Daejeon, South Korea.
Which VCs invest in companies like IntoCell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at IntoCell's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like IntoCell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.